BSE Live
Dec 09, 16:00Prev. Close
1334.60
Open Price
1395.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 09, 15:52Prev. Close
1333.85
Open Price
1372.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Wyeth (in Rs. Cr.) | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 16 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 133.88 | 193.27 | 204.92 | 235.68 | |
| Net CashFlow From Operating Activities | 118.83 | 92.32 | 78.49 | 151.00 | |
| Net Cash Used In Investing Activities | 28.69 | 31.69 | 29.70 | 11.53 | |
| Net Cash Used From Financing Activities | -429.59 | -48.10 | -19.25 | -93.61 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -282.08 | 75.91 | 88.94 | 68.93 | |
| Cash And Cash Equivalents Begin of Year | 439.30 | 363.39 | 274.45 | 205.52 | |
| Cash And Cash Equivalents End Of Year | 157.22 | 439.30 | 363.39 | 274.45 |
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth